Podcast

Handing a Piece of Life Back

Author(s):

Kristie L. Kahl

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

Laurie was no stranger to cancer after she faced a bout with stage 3b non-Hodgkin lymphoma back in 1977, but her second diagnosis of breast cancer left her with a very tough decision on how she wanted to move forward with treatment.

After her oncologist recommended she us a diagnostic test, called the Oncotype DX assay, that helps make informed, individualized treatment decisions, Laurie was able to forgo chemotherapy treatment when she received a recurrence score that indicated that she had a relatively low risk of her cancer returning.

This week, we spoke with Laurie about her treatment decisions, and how this diagnostic test gave her what she calls “a piece of her life back.”

Related Videos
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with a brown hair tied into a bun.
Related Content
An image of a doctor taking notes.
January 24th 2025

Whitesnake Guitarist John Sykes Died of Cancer, Mike Peters Starting CAR-T

Alex Biese
From the deaths of John Sykes and former Planned Parenthood President Cecile Richards to an update from Mike Peters, here’s this week’s cancer news.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Illustration of blood cells.
January 21st 2025

Glucarpidase May Improve Renal Outcomes in Lymphoma, Leukemia

Ryan Scott
Patients with lymphoma or leukemia with methotrexate-induced acute kidney injury experienced improved renal outcomes following glucarpidase treatment.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of hair and scissors.
January 7th 2025

Coming to Terms With Hair Loss After Chemotherapy

Amy Brewster
Losing my hair after chemo was devastating, and I struggled to accept how it changed my appearance and self-image.
CAR-T Cell Therapy in Hematologic Malignancies
January 6th 2025

Understanding the Intricacies of CAR-T Cell Therapy and Care in Hematologic Malignancies

Ryan Scott
Dr. Sattva S. Neelapu discusses the intricacies of CAR T-cell therapy treatment and care for patients with hematologic malignancies.